Puma Biotechnology (PBYI) Projected to Post Quarterly Earnings on Thursday

Puma Biotechnology (NASDAQ:PBYI) is expected to be issuing its Q1 2025 quarterly earnings data after the market closes on Thursday, May 8th. Analysts expect Puma Biotechnology to post earnings of $0.02 per share and revenue of $44.55 million for the quarter. Puma Biotechnology has set its FY 2025 guidance at EPS and its Q1 2025 guidance at EPS.

Puma Biotechnology (NASDAQ:PBYI) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.10 by $0.29. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. The business had revenue of $59.10 million during the quarter, compared to the consensus estimate of $52.50 million. On average, analysts expect Puma Biotechnology to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Puma Biotechnology Stock Performance

Shares of NASDAQ:PBYI opened at $2.98 on Wednesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 1.40. The business’s fifty day moving average price is $3.13 and its two-hundred day moving average price is $3.04. Puma Biotechnology has a fifty-two week low of $2.23 and a fifty-two week high of $5.20. The stock has a market capitalization of $147.90 million, a price-to-earnings ratio of 6.21 and a beta of 1.29.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on PBYI. StockNews.com cut shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Saturday. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Puma Biotechnology in a research note on Friday, February 28th.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.